The UK's drug regulator approved CStone Pharmaceuticals' (HKG:2616) sugemalimab as a first-line treatment for metastatic non-small cell lung cancer (NSCLC).

Sugemalimab, in combination with platinum-based chemotherapy, has been granted authorization as first-line therapy for adult patients suffering from NSCLC without EGFR-sensitive mutations or ALK, ROS1, and RET genomic alterations.

This marks the second overseas approval for sugemalimab following its recent authorization by the European Commission, the drugmaker said in Thursday filing with the Hong Kong Exchange.